Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture.
The antiproliferative activity of 9-beta-D-arabinofuranosyladenine 5'-monophosphate against a cultured line of mouse leukemia cells (L1210/C2) was enhanced by addition of either 2'-deoxycoformycin or erythro-9-(2-hydroxy-3-nonyl)adenine. The activity of 9-beta-D-arabinofuranosyladenine 5'-monophosphate, alone or in combination with either of the two inhibitors of adenosine deaminase, was comparable to that of 9-beta-D-arabinofuranosyladenine (ara-A), apparently reflecting the rapid conversion of 9-beta-D-arabinofuranosyladenine 5'-monophosphate to ara-A by L1210/C2 cells. Several ara-A analogs were assayed for antiproliferative activity against L1210/C2 cells; of these, only 9-beta-D-arabinofuranosyladenine 5'-O-methylphosphate and 2'-deoxy-2'-amino-9-beta-D-arabinofuraosyladenine were active. Addition of 2'-deoxycoformycin to cell culture fluids enhanced the activity of 9-beta-D-arabinofuranosyladenine 5'-O-methylphosphate suggesting conversion to an adenosine deaminase-sensitive intermediate, presumably ara-A.
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives; D058892:Adenosine Deaminase Inhibitors; D000818:Animals; D001088:Arabinonucleotides / Q000008:administration & dosage*; D002455:Cell Division / Q000187:drug effects*; D002478:Cells, Cultured; D003070:Coformycin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004359:Drug Therapy, Combination; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D009700:Nucleoside Deaminases / Q000037:antagonists & inhibitors*; D001084:Vidarabine Phosphate / Q000008:administration & dosage* / Q000031:analogs & derivatives
D058892:Adenosine Deaminase Inhibitors; D001088:Arabinonucleotides; D001084:Vidarabine Phosphate; D003070:Coformycin; D009700:Nucleoside Deaminases; D000225:Adenine